ALSO IN THIS MONTH'S ISSUE

  • What Does The Trump Pivot Mean For Healthcare?
    What Does The Trump Pivot Mean For Healthcare?

    Frustrated with congressional Republican inaction on major pieces of his agenda, President Trump cut deals with Democrats on a short-term increase in the debt ceiling and funding the government. Then to the surprise and consternation of his base, Trump agreed to work on a deal to extend DACA, a Democratic priority. But what does Trump’s new interest in working with Democrats mean for healthcare policy-making? That is not yet clear.

  • A Name Change — And More — For A Biotech
    A Name Change — And More — For A Biotech

    When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.

  • Can AI Deliver Faster, Better Drug Development?
    Can AI Deliver Faster, Better Drug Development?

    As the cost of developing new medicines continues to rise, more pharmaceutical companies are looking at how artificial intelligence (AI) can help in drug development. But there are some hurdles to overcome before its full potential is reached.

  • How Moving Up Through The Ranks Can Shape A Biotech CEO
    How Moving Up Through The Ranks Can Shape A Biotech CEO

    All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

  • Why South Korea Is The Hottest Growth Spot For Clinical Trials
    Why South Korea Is The Hottest Growth Spot For Clinical Trials

    “The Korean pharmaceutical industry has been accelerating investments in open innovation and focusing on R&D for entry into overseas markets,” says Deborah Chee, president, Korean National Enterprise for Clinical Trials.

More from this month's issue

BEYOND THE PRINTED PAGE

  • Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma
    Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Daniel Skovronsky, M.D., Ph.D., is the SVP of clinical and product development at Eli Lilly and Company. But prior to taking on this role, he held the title of CEO of Avid Radiopharmaceuticals — a company he founded in Philadelphia while still a graduate student at the University of Pennsylvania. This article explores some of the differences between this executives past and present roles, and is a good prequel to the upcoming article that explores how he went about building a $300 million company.

  • Does The Biopharmaceutical Industry Need To Broaden Its Horizons?
    Does The Biopharmaceutical Industry Need To Broaden Its Horizons?

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  • What Might Be The Best Predictor Of Future Performance At Axovant Sciences?
    What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

  • Allergan’s Brent Saunders Shares A Social Contract Secret
    Allergan’s Brent Saunders Shares A Social Contract Secret

    Don't miss this free (all-access) sneak peek of our upcoming September feature article on how Brent Saunders built Allergan’s social contract, a document that may likely define his biopharma legacy. “Over time, as people evaluate my leadership in the role, I hope it is not limited to the social contract," he says.

More beyond the printed page articles

WEB-EXCLUSIVE EDITORIAL

  • Investors Drumming Up New Solutions To The Industry’s Real Estate Crunch
    Investors Drumming Up New Solutions To The Industry’s Real Estate Crunch

    Investors are recognizing life sciences real estate as a valuable specialty asset class. In fact, it’s a trend gaining momentum as major real estate investment trusts (REITs) and entrepreneurial investors alike create new homes for life sciences activities.

  • Commissioner Gottlieb, CAR T-Cells, & The Future Of Rare Disease Therapies
    Commissioner Gottlieb, CAR T-Cells, & The Future Of Rare Disease Therapies

    FDA Commissioner Scott Gottlieb has taken the wheel at an exciting time, when insights from genomics are starting to come to fruition and promising new therapies based on new technologies are being developed. This article explores some of the policy changes happening now in the regulatory rare disease space — and shifts we expect to see in the future — as the FDA’s leadership team implements these changes at the agency.

  • How to Get the Maximum Value from Your Market Research Data
    How to Get the Maximum Value from Your Market Research Data

    Generally, the market intelligence that’s behind a successful life science market strategy isn’t public, but if you could take a peek, you’d likely find these four best practices.

  • Leaders: When You Talk, Is Anybody Listening? How to Become an Influential Communicator
    Leaders: When You Talk, Is Anybody Listening? How to Become an Influential Communicator

    Amid today’s rapid-fire business climate and the ever-changing healthcare landscape, it’s not unusual for leaders to move quickly. Fast is fine, but are you going too fast, too often? Are you sure your leadership style isn’t leaving people in the dust or pushing them away?

  • When Regulatory Goes Wrong
    When Regulatory Goes Wrong

    In spite of my preference for “happily ever-after” as detailed in a previous article, sometimes things do not go well for medical device companies as it pertains to regulatory affairs.

  • How Interested Is The FDA In Real-World Evidence?
    How Interested Is The FDA In Real-World Evidence?

    When the Clinical Leader team attended the 2017 DIA Annual Meeting in June, the topic we heard discussed more than any other was real-world evidence (RWE) — that is, information about a drug that is collected outside of clinical trials. RWE is not a new concept, but there are good reasons for all the current attention being paid to it in the pharma industry.

  • Why Pharma Needs A New Approach To Patient Engagement In Drug Development
    Why Pharma Needs A New Approach To Patient Engagement In Drug Development

    Pharmaceutical companies face many challenges: developing life-changing products that meet the needs of patients, physicians, and payers; adhering to regulatory standards; and managing health technology and payer scrutiny, all while trying to satisfy investors. As drug prices seem to be continually rising, many health plans are shifting more of the cost-sharing burden to patients.  As a result, the patient is becoming more of a “consumer” in the traditional sense.

  • Pfenex’s New CEO Sizes Up Biosimilar Industry’s Future
    Pfenex’s New CEO Sizes Up Biosimilar Industry’s Future

    Newly-appointed Pfenex CEO, Eef Schimmelpennink, faces the challenge of determining how to adapt Pfenex to a constantly changing future. Though it's still very early in his tenure, Schimmelpennink highlights some areas he will keep in mind as he steers Pfenex's future biosimilars onto the market.  

More web-exclusive editorial

LIFE SCIENCE TRAINING INSTITUTE COURSES

How to Write SOPs That are GCP Compliant and Implementable October 17, 2017
1pm-2:30pm EDT, Online Training
Improving Biological Facility Design: Critical Tips for Compliance October 18, 2017
1pm-2:30pm EDT, Online Training
The Investigational New Drug (IND) Submission - Tips to Win the First Time October 26, 2017
1pm-2:30pm EST, Online Training
More training courses

OCTOBER 2017 DIGITAL EDITION

2017 CMO & CRO AWARDS EDITIONS

   

@LIFESCILEADER1

 UPCOMING EVENTS

How to Write SOPs That are GCP Compliant and Implementable October 17, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Outsourced Pharma October 17 - 18, 2017
San Francisco , CA
Outsourced Pharma October 17 - 18, 2017
San Francisco , CA
BIO Investor Forum October 17 - 18, 2017
San Francisco, CA
Improving Biological Facility Design: Critical Tips for Compliance October 18, 2017
1pm-2:30pm EDT, Online Training
Price:  $299
More events